Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: TNBC - Triple-Negative Breast Cancer
Interventions: DRUG: Gedatolisib|DRUG: Talazoparib
Sponsor: Kari Wisinski
Collaborators: Pfizer|Celcuity Inc